RecruitingEarly Phase 1NCT07530380
UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
Studying Autoimmune hemolytic anemia, warm type
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Second Hospital of Anhui Medical University
- Principal Investigator
- ZhaiThe Second Hospital of Anhui Medical University
- Intervention
- QT-219C Cell Injection(biological)
- Enrollment
- 15 target
- Eligibility
- 10 years · All sexes
- Timeline
- 2026 – 2030
Study locations (1)
- The Second Hospital of Anhui Medical University, Hefei, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07530380 on ClinicalTrials.govOther trials for Autoimmune hemolytic anemia, warm type
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07039422Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabNovartis Pharmaceuticals
- RECRUITINGNANCT05925023Sirolimus in the Treatment of Refractory/Relapsed wAIHAPeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT05648968A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2NCT05002777Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)Sanofi
- ACTIVE NOT RECRUITINGPHASE2NCT04657094Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic LeukemiaCity of Hope Medical Center